Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > AS1404

AS1404 : Antisoma : vascular disrupting agent

Preliminary Phase II Data for AS1404 in Lung Cancer (Antisoma)
Press release announcing preliminary findings from an ongoing phase II trial of AS1404 in lung cancer. Preliminary data from 47 of 71 enrolled patients found those receiving AS1404 in addition to chemotherapy showed a higher frequency of tumor response (43.5% vs 33.3%) and a lower frequency of progressive disease (8.7% vs 33.3%) than those receiving chemotherapy alone. [10/05]


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor